ARTICLE | Company News
Helsinn Healthcare SA, Rafa Ltd. sales and marketing update
October 11, 2004 7:00 AM UTC
Rafa received exclusive rights to distribute palonosetron in Israel to prevent nausea and vomiting associated with chemotherapy. The selective serotonin (5-HT3) receptor antagonist is marketed in the...